Bio

Michael Schlander, M.D., Ph.D., M.B.A., is a professor of health economics with background as medical doctor and economist, with substantial international management and consulting experience.

Academic Roles

• Foundation Chairman & Scientific Director of the not-for-profit Institute for Innovation & Valuation in Health Care (InnoVal^HC, since June 2005)
• Univ.-Prof. em. of Health Economics at the University of Heidelberg, granted leave of absence (from 01 January 2017 to 30 September 2025) to establish and lead the former Division of Health Economics at the German Cancer Research Center (DKFZ)
• Board Member of the Health Economics Working Group of the Organisation of European Cancer Institutes (OECI, since 2020)
• Founder & Head of the Task Force on “Socioeconomic Impact Research” of the OECI (since March 2021)
• Member of the Editorial Boards for the peer-reviewed journals "Zeitschrift für medizinische Ethik" (ZfmE, Journal of Medical Ethics, since 2023) and "Frontiers in Health Service" (since 2022)

Prior Academic Roles

• Professor of Business Administration and (Technology, Innovation, Life Sciences & Health Care) Management (September 2002 – December 2016; position offered in January 2002, accepted: February 2002) at the University of Applied Economic Sciences Ludwigshafen / Germany; focus on health economics, health care management, and innovation management; inauguration of a new international study program in innovation management (leading students to the degree of Master of Arts, M.A.)
• Health Economist at the University of Heidelberg / Germany, Mannheim Institute of Public Health, Social Preventive Medicine (2007-2016)
• Member of Scientific Course Committee, Postgraduate Program in Pharmaceutical Medicine, responsible for courses in health economics and innovation management at the University of Duisburg-Essen / Germany (2005-2008); before that, founding member of Scientific Course Committee, Postgraduate Program in Pharmaceutical Medicine, and Member of Faculty of Medicine, University of Witten/Herdecke / Germany (1996-2005)

Selected Academic Offers

received during tenured professorship at University of Applied [Economic] Sciences Ludwigshafen:

• Full University Professorship (Chair) of Health Economics
  (at the Mannheim Medical Faculty of the University of Heidelberg,
  granting leave of absence to establish and lead a Division of Health Economics at the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ)
  listed primo et unico loco – accepted in September 2016.
• January 2011
  Full Professorship (“W3”) for Health Economics
  (at the Mannheim Medical Faculty of the University of Heidelberg)
  listed primo loco – not accepted
• April 2009
  Head of Health Economics Department
  for a major official HTA Agency in Europe – not accepted
• June 2008
  Worldwide Vice President, Health Economics, Market Access & Pricing
  (for a top-10 research-based pharmaceutical corporation)
  position directly reporting to the Board of Management – not accepted 

Academic Background

• Scientific Program Committee Chair
  of ISPOR (International Society for Pharmacoeconomics and Outcomes Research) 15th Annual European Congress in Berlin, Germany, November 3-7, 2012

  [The ISPOR Annual European Meetings are the most important convention of health economists and health care policy makers in Europe. The Berlin conference was attended by more than 3,500 delegates and saw a record submission of close to 2,000 scientific presentations.]

• "Habilitation" (venia legendi, Ph.D. equivalent)
  in Health Economics,
  University of Heidelberg / Germany
  November 2007
• Diploma in Health Economics,
  Stockholm School of Economics / Sweden
  (Handelshögskolan i Stockholm),
  June 2002
• Master of Business Administration (M.B.A.),
  City University of Seattle / Washington / U.S.A.
  (Valedictorian of the class of 1994)
• Dr. med. (M.D.),
  University of Frankfurt am Main / Germany
  (Dissertation in experimental brain research;
  grade "summa cum laude"), January 1987
• Licensed as a physician in Germany,
  since November 1985

Academic Prizes and Awards

• Best General Poster Research Presentation Award (out of ~2500 presentations) with Ramon Schaefer [first author] at the Annual European ISPOR Congress, Copenhagen, Denmark, November 2023
• ISPOR Distinguished Service Award for acting as ISPOR 15^th Annual European Congress Program Chair, Berlin, Germany, November 2012
• Best Contributed Poster Presentation Award (out of ~750 presentations) at the Annual European ISPOR Congress, Florence, Italy, November 2005

Major Areas of Scientific Interest

Please refer to “Research” and to “Institute for Innovation & Valuation in Health Care”.

Presentations & Publications

Michael Schlander’s scientific presentations & publications focused predominantly on the fields of experimental brain research, innovation and technology management, strategic management, health care management, health economics, and health policy, including Health Technology Assessment. More than 500 scientific contributions to international meetings and journals have been documented in periodicals,

including (in alphabetical order):

ADHD – Attention Deficit Hyperactivity Disorders; American Journal of Psychiatry; Anatomy & Embryology; Annals of Haematology; Applied Clinical Trials; Applied Health Economics and Health Policy; Applied Research in Quality of Life; BMC Cancer; BMC Medical Research Methodology; Brain Research; Cancer Medicine; Cell and Tissue Research; Child and Adolescent Psychiatry and Mental Health (CAPMH); Clinical Gastroenterology and Hepatology; Current Medical Research & Opinion; Current Pharmaceutical Design; Drug Information Association (DIA) Global Forum; Drug Information Journal; European Child and Adolescent Psychiatry; European Journal of Clinical Chemistry & Clinical Biochemistry; European Journal of Psychiatry; Expert Reviews in Pharmacoeconomics and Outcomes Research; Frontiers in Public Health; Gastroenterology; Gastrointestinal Endoscopy; Gut; Health Affairs; Health and Quality of Life Outcomes; Health Services Research; International Journal of Cancer; International Journal of Clinical Pharmacology and Therapeutics; International Journal of Health Policy and Management; ISPOR Connections; JAMA Psychiatry; Journal of Clinical Anesthesia; Journal of Cancer Research and Clinical Oncology; Journal of Cancer Survivorship; Journal of Comparative Effectiveness Research; Journal of Gastrointestinal Cancer, Journal of Human Development and Capabilities; Journal of Market Access & Health Policy; Journal of Medical Ethics; Journal of Public Health; The Lancet; The Lancet Oncology; MDM Policy & Practice; Medicine, Health Care and Philosophy; Neuroscience; Neuroscience Letters; Oncology Research; Orphanet Journal of Rare Diseases; Pharmaceutical Executive; The Patient; PharmacoEconomics; PharmacoEconomics Open; Public Health Ethics; Progress of Clinical & Biological Research; Value in Health

as well as a number of German periodicals, such as

AMOS International; Ärztliches Labor; Bundesgesundheitsblatt; Deutsches Ärzteblatt; Forum; Frankfurter Allgemeine Zeitung (FAZ); Gesellschaftspolitische Kommentare; Gesundheitsökonomie & Qualitätsmanagement; Kassenarzt; Medizinische Klinik; Medizinische Welt; Münchner Medizinische Wochenschrift (MMW) / Fortschritte der Medizin; Nervenarzt; Neue Zürcher Zeitung (NZZ); Nieren- und Hochdruckkrankheiten; Onkologie; Der Onkologe; PharmInd – Die pharmazeutische Industrie; psychoneuro; Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen (ZEFQ)

A complete list of publications will be provided on request.

For further information on some publications of general interest, please also refer to “Publications” and to “Presentations”.

Membership in Scientific Associations

Michael Schlander has been a member of numerous scientific and professional associations, including the following:

• Organisation of European Cancer Institutions (OECI). Health Economics Working Group (Board Member, since 2020) and Task Force on Socioeconomic Impact Research (Chair, since March 2021)
• International Health Economics Association (iHEA)

• International Society for Pharmaoeconomics and Outcomes Research (ISPOR)

  [Michael Schlander served as scientific chair of the 15th Annual European ISPOR Congress in Berlin / Germany, November 03-07, 2012]

• Product Development & Management Association (pdma)
• Drug Information Association (DIA)
• Association of German speaking economists (Verein für Socialpolitik)
• Alliance for the Advancement of Applied Health Economics (A³HE)

• German Society for Health Economics (DGGOe)

  [Michael Schlander was one of the 17 German university professors who founded the DGGOe at a meeting in Berlin / Germany, October 17, 2008.]

• German Society for Pharmaceutical Medicine (Deutsche Gesellschaft für Pharmazeutische Medizin, DGPharMed)
• Association of Medical & Scientific Journalists (Verband der Medizin- & Wissenschaftsjournalisten, VMWJ)
• Frankfurt Medical Society (Frankfurter Medizinische Gesellschaft, FMG)

Professional Background

Professional experience gathered in Germany, Belgium, Switzerland, and the United States of America:

• Professor of Health Economics
  
  University of Heidelberg (Mannheim Medical Faculty and Alfred Weber Institute of Economics),
  on leave of absence to establish and lead the former Division of Health Economics at the German Cancer Research Center (DKFZ)
  (January 1, 2017 – September 30, 2025)
• Professor of Business Administration and Management
  (Focus on Health Care & Innovation Management)
  
  University of Applied Economic Sciences / Hochschule (für Wirtschaft) Ludwigshafen am Rhein
  (September 1, 2002 – December 31, 2016)
  
  Member of commission for "Good Scientific Practice"
• Managing Director
  
  Biopharmaceutical & Medical Device Industry (Germany)
  (August 1, 1999 – August 31, 2002)
  
  Turn around and strategic change management;
  achieving sustained double-digit organic growth and double-digit return on revenues after a long-standing decline of market share, shrinking sales and substantial loss prior to taking over leadership
• Strategic & International Marketing / Business Unit Leadership
  
  Biopharmaceutical Industry (Germany, Belgium, and United States)
  (September 1, 1993 – July 31, 1999)
  
  Inter alia, building, from scratch, a worldwide operating Strategic Business Unit (“Gastroenterology; responsibility for functional areas including project management, clinical development, international medical communications, international marketing, domestic marketing & sales management); leading one of the most successful new product launches of the German pharmaceutical industry (pantoprazole)
• Clinical Research and Development
  
  Biopharmaceutical Industry (Germany and Switzerland)
  (September 1, 1987 – August 31, 1993)
  
  Leading successful European new product development programs
  (in cardiovascular medicine, immunology, supportive cancer care)
• Experimental Brain Research and Clinical Neurology
  
  (April 1, 1982 - August 31, 1987)
  
  Universities of Frankfurt am Main and Mainz (Germany)
  
  Combined light and electron microscopic studies of identified neurons in the hippocampus of the mammalian and the human brain (including M.D. thesis project); clinical residency in neurology.